{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-265830","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2026-06-10T20:09:58+00:00","discovered_at":"2026-06-10T20:11:04.191068+00:00","generated_at":"2026-06-10T20:11:55.185330+00:00","sec_items":["5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"enGene shareholders re-elect all four directors, ratify auditor at 2026 AGM","bullets":["56,196,302 common shares voted (83.89% of outstanding) at June 9, 2026 AGM.","All four director nominees elected with >99% votes cast in favor; broker non-votes ~8.8M.","Auditor appointment and remuneration approved: 56,180,287 for, 16,015 against.","No other significant proposals; no change in board composition or auditor."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-265830","json":"https://secwatch.observer/filing/0001193125-26-265830.json","markdown":"https://secwatch.observer/filing/0001193125-26-265830.md","text":"https://secwatch.observer/filing/0001193125-26-265830.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526265830/0001193125-26-265830-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526265830/engn-20260609.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T20:11:55.185330+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3caf55b4dcb9f9de241eb2eb0b8d1de7b3faa1de","claim":"enGene Therapeutics Inc. shareholders approved Appointment and Remuneration of Auditor at the 2026-06-09 meeting.","evidence_excerpt":"Proposal 2 – Appointment and Remuneration of Auditor For Withhold Broker Non-Votes 56,180,287 16,015 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526265830/0001193125-26-265830-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"91906698ad7269a2bc512407f2b454113dae44df","claim":"enGene Therapeutics Inc. shareholders approved Election of Directors at the 2026-06-09 meeting.","evidence_excerpt":"Proposal 1 – Election of Directors Director Nominee For Withhold Broker Non-Votes Philip Astley-Sparke 47,112,414 306,821 8,777,067 Ronald H.W. Cooper 47,329,848 89,387 8,777,067 Dr. William Grossman 47,408,163 11,072 8,777,067 Michael Heffernan 47,408,163 11,072 8,777,067","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526265830/0001193125-26-265830-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}